In this issue:
- Trifluridine/tipiracil + bevacizumab for heavily pre-treated mCRC
- An early prognosis and detection method for CRC using ctDNA methylation haplotype patterns
- Risk of obesity-related cancer in metabolically healthy vs. unhealthy individuals
- Adagrasib ± cetuximab in KRAS G12C-mutated CRC
- CAPSTAN CRC: real-world first-line treatment patterns in BRAFV600E-mutated mCRC
- CanStem303C: Napabucasin + FOLFIRI in previously-treated mCRC
- Meta-analysis of HER2-targeted therapy in CRC
- Interactions between chemotherapy & concomitant PPIs in CRC
- Neoadjuvant anti-PD-1 treatment in localised dMMR CRC
- FOLFOX in mCRC to extrahepatic sites
Please login below to download this issue (PDF)